A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Future Oncol
; 13(28): 2537-2546, 2017 Dec.
Article
em En
| MEDLINE
| ID: mdl-29086616
Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pleurais
/
Inibidores da Angiogênese
/
Bevacizumab
/
Antineoplásicos Imunológicos
/
Neoplasias Pulmonares
/
Mesotelioma
Tipo de estudo:
Clinical_trials
/
Guideline
/
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2017
Tipo de documento:
Article